Thu, Aug 21, 2014, 11:36 AM EDT - U.S. Markets close in 4 hrs 24 mins

Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • spencer_doc spencer_doc Nov 2, 2012 3:10 PM Flag

    Motley Fool .Goldman Bashing VRTX. That's the problem. read

    Motley Fool 11/2/12
    Saying it's "more cautious" about Vertex's drug pipeline, Goldman runs down a list of clinical trials Vertex drugs are undergoing, ticking each off, one at a time, and explaining why it sees none of them as likely "catalysts" to drive the stock upwards. The analyst isn't particularly enthused over Vertex's "recently announced cross-company collaborations" with Johnson & Johnson (NYSE: JNJ ) and GlaxoSmithKline (NYSE: GSK ) either, arguing that these arrangements "do not change the fundamental value of VRTX's nuc (VX-135)." (That's Vertex's hepatitis C drug).

    But what about the value of the stock? At 23 times earnings, Vertex doesn't look particularly expensive for a drug stock (many of which have no profits at all, and so no P/E ratios). That said, if Vertex only grows earnings at 19% per year going forward, the consensus estimate for such growth, then 23 times earnings may in fact be a bit too expensive for the growth rate. What's more, Goldman thinks Vertex will struggle to hit even the 19%. Looking out toward fiscal year 2015, Goldman says it's expecting revenues will grow no faster than at 10% ... and perhaps won't grow at all, but rather shrink 2%.

    Conclusion: If everything goes wrong, and Vertex "misses" its numbers, the stock's badly overvalued. If everything right, and Vertex meets expectations, the company's only slightly overvalued. Suffice it to say that this does not bode well for investors.

 
VRTX
89.10-2.20(-2.41%)11:36 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.